Immunologic targeting of the cancer stem cell

[1]  Mina J Bissell,et al.  Is CD133 a marker of metastatic colon cancer stem cells? , 2008, The Journal of clinical investigation.

[2]  A. Strasser,et al.  Is tumor growth sustained by rare cancer stem cells or dominant clones? , 2008, Cancer research.

[3]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[4]  M. Schmitt,et al.  Leukemia‐associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia , 2008, European journal of haematology.

[5]  P. Pedrazzoli,et al.  Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors , 2008, Nature Clinical Practice Oncology.

[6]  H. Levitsky,et al.  The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  Kornelia Polyak,et al.  The cancer stem cell hypothesis: in search of definitions, markers, and relevance , 2008, Laboratory Investigation.

[8]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[9]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[10]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[11]  J. Crowley,et al.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Neuberg,et al.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma , 2008, Proceedings of the National Academy of Sciences.

[13]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[14]  R. Pazdur,et al.  Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.

[15]  J. Chewning,et al.  Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands , 2007, The Journal of Immunology.

[16]  Z. Rudzki,et al.  BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria , 2007, Clinical Cancer Research.

[17]  K. Rezvani,et al.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.

[18]  Catherine J. Wu,et al.  Proteomics To Identify Novel Immune-Targeted CML Stem Cell Antigens. , 2007 .

[19]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[20]  Marcela R. Uribe,et al.  Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia , 2007, Leukemia.

[21]  D. Douek,et al.  Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. , 2007, Blood.

[22]  C. Sawyers,et al.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.

[23]  Aleksandar Dakic,et al.  Tumor Growth Need Not Be Driven by Rare Cancer Stem Cells , 2007, Science.

[24]  K. Dietz,et al.  Intensity of HLA class I expression and KIR‐mismatch determine NK‐cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia , 2007, British journal of haematology.

[25]  J. Radich,et al.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. , 2007, Blood.

[26]  G. Perrone,et al.  Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. , 2007, Cancer research.

[27]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[28]  R. Larson,et al.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.

[29]  J. Powell,et al.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. , 2007, Blood.

[30]  C. Eaves,et al.  Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. , 2007, Journal of the National Cancer Institute.

[31]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[32]  T. Holyoake,et al.  Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. , 2007, Blood.

[33]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[34]  J. Crowley,et al.  Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathy , 2007, The Journal of experimental medicine.

[35]  M. Baccarani,et al.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.

[36]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[37]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[38]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[39]  J. Ritz,et al.  Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. , 2007, Blood.

[40]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[41]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[43]  Louis Gaboury,et al.  SP analysis may be used to identify cancer stem cell populations. , 2006, Experimental cell research.

[44]  F. Menghi,et al.  Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. , 2006, Cancer research.

[45]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[46]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[47]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[48]  A. Anichini,et al.  Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.

[49]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[50]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[51]  F. Hodi,et al.  Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[53]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Goldhirsch,et al.  Breast cancer vaccines: a clinical reality or fairy tale? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  M. Little,et al.  A Side Order of Stem Cells: The SP Phenotype , 2006, Stem cells.

[56]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[58]  J. Falkenburg,et al.  Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia. , 2005, Blood.

[59]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[60]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  T. Uchiyama,et al.  Identification of APOBEC3B as a potential target for the graft‐versus‐lymphoma effect by SEREX in a patient with mantle cell lymphoma , 2005, British journal of haematology.

[62]  M. Martelli,et al.  The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. , 2005, Transplant immunology.

[63]  F. Pijpers,et al.  Therapeutic cancer vaccines , 2005, Nature Reviews Drug Discovery.

[64]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[65]  J. Kutok,et al.  Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells , 2005, Clinical Cancer Research.

[66]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[67]  Bingyan Wu,et al.  Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. , 2005, Blood.

[68]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  M. Martelli,et al.  Natural killer cell alloreactivity for leukemia therapy. , 2005, Journal of immunotherapy.

[70]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[71]  L. Hambach,et al.  Immunotherapy of cancer through targeting of minor histocompatibility antigens. , 2005, Current opinion in immunology.

[72]  K. Hsu,et al.  Natural killer cell receptors: regulating innate immune responses to hematologic malignancy. , 2005, Seminars in hematology.

[73]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  E. Jaffee,et al.  Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. , 2005, Cancer research.

[75]  F. Vély,et al.  Coordination of activating and inhibitory signals in natural killer cells. , 2005, Molecular immunology.

[76]  C. Craddock,et al.  Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. , 2004, Blood.

[77]  E. Warren,et al.  A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene1 , 2004, The Journal of Immunology.

[78]  F. Giles,et al.  The Spermatozoa Protein, SLLP1, Is a Novel Cancer–Testis Antigen in Hematologic Malignancies , 2004, Clinical Cancer Research.

[79]  K. Kuzushima,et al.  Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response , 2004, Bone Marrow Transplantation.

[80]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[81]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[83]  S. Riddell,et al.  Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.

[84]  R. Verdijk,et al.  Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. , 2004, Blood.

[85]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[86]  Catherine J. Wu,et al.  Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. , 2004, Blood.

[87]  D. Scheinberg,et al.  A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. , 2004, Blood.

[88]  Mads Hald Andersen,et al.  Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles , 2004, Cancer biology & therapy.

[89]  L. Moretta,et al.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors , 2004, The EMBO journal.

[90]  Catherine J. Wu,et al.  Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. , 2004, Blood.

[91]  J. Raemaekers,et al.  Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation , 2003, Bone Marrow Transplantation.

[92]  Irving L Weissman,et al.  Biology of hematopoietic stem cells and progenitors: implications for clinical application. , 2003, Annual review of immunology.

[93]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[94]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[95]  Irving L. Weissman,et al.  Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[97]  E. Warren,et al.  The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. , 2003, Blood reviews.

[98]  M. Boccadoro,et al.  Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. , 2003, Blood.

[99]  D. Neuberg,et al.  Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  B. Abbott.  ABCG2 (BCRP) expression in normal and malignant hematopoietic cells , 2003, Hematological oncology.

[101]  T. Mutis,et al.  Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation , 2003, The Lancet.

[102]  M. Becker,et al.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[103]  J. Shabanowitz,et al.  The minor Histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein , 2003 .

[104]  E. Simpson,et al.  Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. , 2003, Blood.

[105]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[106]  T. Naoe,et al.  Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens , 2003, The Journal of experimental medicine.

[107]  E. Warren,et al.  A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion , 2003, The Journal of experimental medicine.

[108]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[109]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[111]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Ken Jung,et al.  Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[114]  D. Pardoll,et al.  Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. , 2003, Blood.

[115]  P. Kantoff,et al.  CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. , 2002, Cancer research.

[116]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[117]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[118]  C. Sawyers,et al.  Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[119]  Catherine J. Wu,et al.  Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. , 2002, Blood.

[120]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[121]  N. Hosen,et al.  patients with hematopoietic malignancies product in WT 1 Humoral immune responses against Wilms tumor gene , 2002 .

[122]  R. Herrmann,et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.

[123]  J. Drijfhout,et al.  The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. , 2002, Blood.

[124]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[125]  S. Fujita,et al.  Identification of a novel WT1‐derived peptide which induces human leucocyte antigen‐A24‐restricted anti‐leukaemia cytotoxic T lymphocytes , 2002, British journal of haematology.

[126]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[127]  G. Dranoff,et al.  Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. , 2002, Cancer research.

[128]  S. Amigorena,et al.  Fcγ Receptors and Cross-Presentation in Dendritic Cells , 2002, The Journal of experimental medicine.

[129]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[130]  M. Talpaz,et al.  Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[131]  J. Shabanowitz,et al.  The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein , 2001, The Journal of Immunology.

[132]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[133]  P. Kantoff,et al.  CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[134]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[135]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[136]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[137]  J. Esteve,et al.  Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status , 2001, Leukemia.

[138]  L. Carter,et al.  WT1-specific serum antibodies in patients with leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  J. Shabanowitz,et al.  The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing , 2001, The Journal of experimental medicine.

[140]  J. Falkenburg,et al.  UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. , 2000, Blood.

[141]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[142]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[143]  D. Neuberg,et al.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[144]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[145]  C. Mullen,et al.  Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. , 2000, Blood.

[146]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[147]  J. Falkenburg,et al.  DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. , 2000, Blood.

[148]  H. Sugiyama,et al.  Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.

[149]  J. Shabanowitz,et al.  Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. , 1999, Journal of immunology.

[150]  A. Gratwohl,et al.  Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation , 1999, Bone Marrow Transplantation.

[151]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[152]  J. Connors,et al.  Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[153]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[154]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[155]  A. Tosti,et al.  Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. , 1999, Blood.

[156]  S. H. Lim,et al.  Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. , 1998, Blood.

[157]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[158]  N. Ueno,et al.  Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  D. Neuberg,et al.  Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. , 1998, Blood.

[160]  J. Falkenburg,et al.  Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay , 1998, Bone Marrow Transplantation.

[161]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[162]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[163]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[164]  M. Pfreundschuh,et al.  Serological identification of human tumor antigens. , 1997, Current opinion in immunology.

[165]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[166]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[167]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Labopin,et al.  Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[169]  M. Andreeff,et al.  Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. , 1996, Bone marrow transplantation.

[170]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[171]  B. Barlogie,et al.  Graft-versus-myeloma effect: proof of principle. , 1996, Blood.

[172]  A. Agulnik,et al.  Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. , 1995, Science.

[173]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[174]  C. Perreault,et al.  Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  J. Sidney,et al.  Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. , 1995, Blood.

[176]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[177]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[178]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[179]  D. Page,et al.  The human Y chromosome: overlapping DNA clones spanning the euchromatic region. , 1992, Science.

[180]  R. Collins,et al.  Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. , 1992, Bone marrow transplantation.

[181]  R. Truitt,et al.  Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. , 1991, Bone marrow transplantation.

[182]  S. Piantadosi,et al.  Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. , 1991, Blood.

[183]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[184]  L. Barnett,et al.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.

[185]  M. Pepe,et al.  Previous donor pregnancy as a risk factor for acute graft‐versus‐host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation , 1990, British journal of haematology.

[186]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[187]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[188]  K. Sullivan,et al.  HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. , 1988, Blood.

[189]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[190]  A. Butturini,et al.  Graft-versus-leukemia following bone marrow transplantation. , 1987, Bone marrow transplantation.

[191]  A I Goldman,et al.  Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[192]  J. Biggs,et al.  Female marrow donors increase the risk of acute graft‐versus‐host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum , 1986, British journal of haematology.

[193]  K. Anderson,et al.  Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. , 1986, Blood.

[194]  H. Koeffler,et al.  Chronic Myelocytic Leukaemia: a Pluripotent Haemopoietic Cell is Involved in the Malignant Clone , 1981, British journal of haematology.

[195]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[196]  V. Najfeld,et al.  Involvement of the B-lymphoid system in chronic myelogenous leukaemia , 1980, Nature.

[197]  J. Adamson,et al.  Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia (CML) following a chemotherapy-induced loss of the Ph1 chromosome. , 1980, Blood.

[198]  A. Levine,et al.  Chronic myelocytic leukemia: eosinophils involved in the malignant clone. , 1980, Blood.

[199]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[200]  D. Peakman,et al.  REMISSION OF RELAPSED LEUKÆMIA DURING A GRAFT-VERSUS-HOST REACTION A "GRAFT-VERSUS-LEUKÆMIA REACTION" IN MAN? , 1978, The Lancet.

[201]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[202]  G. Saglio,et al.  Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories , 2008, Leukemia.

[203]  R M Stone,et al.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib , 2008, Leukemia.

[204]  M. Gordon.  Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .

[205]  M. Baccarani,et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy , 2007 .

[206]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[207]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[208]  J. Ritz,et al.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.

[209]  M. Slovak,et al.  Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. , 2003, Blood.

[210]  T. Mutis,et al.  Targeting alloreactive T cells to hematopoietic system specific minor histocompatibility antigens for cellular immunotherapy of hematological malignancies after stem cell transplantation. , 2002, Annals of hematology.

[211]  Sante Tura,et al.  A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.

[212]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[213]  B. Druker,et al.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.

[214]  T. Schumacher,et al.  In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens , 2002, Nature Medicine.

[215]  M. Kaplan,et al.  Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. , 2002, The Journal of experimental medicine.

[216]  H. V. van Houwelingen,et al.  Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. , 2001, The hematology journal : the official journal of the European Haematology Association.

[217]  G. Saglio,et al.  Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. , 2001, Haematologica.

[218]  C. Craddock,et al.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2000, Blood.

[219]  A. Barrett,et al.  Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation , 1997, Annals of Hematology.

[220]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[221]  J. Ritz,et al.  Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[222]  I. Bernstein,et al.  Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. , 1992, Blood.

[223]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[224]  K. Sullivan,et al.  Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. , 1987, Progress in clinical and biological research.

[225]  J. Singer,et al.  Chronic myelocytic leukemia (CML): failure to detect residual normal committed stem cells in vitro. , 1979, Blood.

[226]  D. Peakman,et al.  Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? , 1978, Lancet.